A recent Brazilian study published in Nature Cardiovascular Research has highlighted promising pathways for preventing and ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation.

A new study has found that prescribing blood thinners to adults under 65 with atrial fibrillation (AFib) but no other health risks does not help prevent stroke, mini-stroke (TIA), or memory problems.

Switching from beta-blockers to digoxin as first line therapy for older patients with AF could produce £100m in NHS savings annually.

Cardiovascular Services The Heart Center at St. Mark’s offers a variety of services for people with heart conditions. The ...

Mount Carmel’s heart and vascular teams have debuted several new, highly advanced surgical procedures in Central Ohio.

New e-book explores transformative medtech advancements in pulsed field ablation for atrial fibrillation treatment. LONDON, Feb. 4, 2025 /CNW/ -- Clarivate Plc (NYSE:CLVT) a leadi ...

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.